What is Leerink Partnrs’ Estimate for FATE Q1 Earnings?

Fate Therapeutics, Inc. (NASDAQ:FATE) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Fate Therapeutics in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings of ($0.46) per share for the quarter. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share. Leerink Partnrs also issued estimates for Fate Therapeutics’ Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.50) EPS and FY2029 earnings at ($1.34) EPS.

Fate Therapeutics (NASDAQ:FATE) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.02. The company had revenue of $3.07 million for the quarter, compared to analysts’ expectations of $0.88 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%.

Several other analysts also recently commented on FATE. Needham & Company LLC reiterated a “hold” rating on shares of Fate Therapeutics in a report on Tuesday, November 19th. Wedbush reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of Fate Therapeutics in a research report on Tuesday, November 12th. Finally, Bank of America raised shares of Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Monday, November 18th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $6.75.

Fate Therapeutics Trading Up 11.8 %

NASDAQ FATE opened at $1.42 on Friday. The firm has a market capitalization of $161.73 million, a P/E ratio of -0.86 and a beta of 2.02. The business has a fifty day simple moving average of $1.55 and a 200 day simple moving average of $2.66. Fate Therapeutics has a 12 month low of $1.04 and a 12 month high of $8.83.

Insider Activity at Fate Therapeutics

In other news, Director Redmile Group, Llc acquired 397,964 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were acquired at an average cost of $1.68 per share, for a total transaction of $668,579.52. Following the purchase, the director now owns 12,884,277 shares of the company’s stock, valued at approximately $21,645,585.36. The trade was a 3.19 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Fate Therapeutics

Several large investors have recently modified their holdings of the business. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Fate Therapeutics during the 4th quarter valued at approximately $195,000. Dark Forest Capital Management LP raised its holdings in Fate Therapeutics by 128.0% during the 4th quarter. Dark Forest Capital Management LP now owns 61,220 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 34,371 shares during the period. Hsbc Holdings PLC lifted its position in shares of Fate Therapeutics by 22.0% during the fourth quarter. Hsbc Holdings PLC now owns 109,422 shares of the biopharmaceutical company’s stock worth $179,000 after acquiring an additional 19,706 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Fate Therapeutics by 10.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,898,377 shares of the biopharmaceutical company’s stock worth $4,782,000 after acquiring an additional 279,360 shares during the period. Finally, Marshall Wace LLP purchased a new position in shares of Fate Therapeutics in the fourth quarter valued at $846,000. Hedge funds and other institutional investors own 97.54% of the company’s stock.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.